Clinical trials exploring targeting IL-12/IL-23 and IL-6 inhibition in prophylaxis and treatment of GVHD are ongoing (Tvedt et al., 2017; Hill and Koyama, 2020). The gene discussed is IL6; the disease is graft versus host disease.